MxB Disrupts Hepatitis C Virus NS5A–CypA Complex: Insights From a Combined Theoretical and Experimental Approach

Quanjie Li, Ni An, Yin Xiao, Ruixin Zhang, Huihan Shao, Dongrong Yi, Shan CenFrontiers in Microbiology 2022 · DOI

This study, published in Frontiers in Microbiology, provides a detailed molecular map of how the human protein MxB acts as an innate "security guard" against the Hepatitis C Virus (HCV). By combining computer simulations with wet-lab experiments, the researchers discovered that MxB functions like a molecular wedge, binding to the viral protein NS5A and weakening its essential interaction with a host helper protein, Cyclophilin A (CypA), by roughly 28%.

TL;DR

Researchers have decoded the molecular mechanism by which the host protein MxB inhibits Hepatitis C. MxB binds to the viral protein NS5A, energetically destabilizing its bond with host factor CypA and effectively "short-circuiting" the virus's ability to replicate.

What Problem Does This Paper Address?

Hepatitis C Virus (HCV) is a master of hijacking host cell machinery. To replicate its RNA, it relies on a critical partnership between its own protein, NS5A, and a host protein called Cyclophilin A (CypA). If you disrupt this "handshake," the virus cannot multiply.

The human body has a natural defense called MxB (myxovirus resistance B), an interferon-induced protein known to restrict several viruses, including HIV-1 and HCV. While scientists knew MxB interfered with the NS5A–CypA complex, the exact "how" remained a structural black box. This paper aims to identify the specific amino acids involved in this three-way molecular tug-of-war.

Methods

The authors employed a "Combined Theoretical and Experimental Approach":

  • Structural Modeling: Since full-length structures for these proteins in complex weren't available, they used I-TASSER for ab initio modeling and threading.
  • Protein-Protein Docking: They used HADDOCK and ZDOCK to predict how MxB, NS5A, and CypA physically fit together.
  • Molecular Dynamics (MD) Simulations: Using Amber11, they simulated the stability of these complexes in a water environment for 10 nanoseconds to calculate binding energies (via the MM/GBSA method).
  • Biochemical Validation: To prove the computer models were right, they created truncation mutants (shortened versions of the proteins) and used Co-Immunoprecipitation (Co-IP) and Western Blotting to see which parts were truly essential for binding.
  • Viral Infection Assays: They used the Jc1 HCVcc virus strain to measure how different MxB mutants affected actual viral replication.

Datasets

The study relied on established protein structures from the Protein Data Bank (PDB):

  • MxB: PDB ID 4WHJ (crystal structure of the GTPase and stalk domains).
  • NS5A Domain I: PDB ID 3FQM.
  • CypA: PDB ID 1YND.
  • Template for modeling: PDB ID 3OSR (Maltose-binding periplasmic protein).

Key Insights and Ideas

  • The "Wedge" Mechanism: Interestingly, MxB and CypA do not bind to the exact same spot on NS5A. MxB binds to Domain I, while CypA primarily targets Domain II/III. Despite this, MxB's presence creates an "allosteric" or energetic disturbance that weakens the CypA-NS5A bond.
  • Specific "Hot Spots": The study pinpointed specific amino acids: MxB residues 189–191 and 330–334 are the "fingers" that grab NS5A at residues 71–73.
  • Stronger Affinity Wins: The binding energy between MxB and NS5A (~ -105 kcal/mol) is significantly stronger than the bond between CypA and NS5A (~ -61 kcal/mol). MxB essentially out-competes the host factor for the virus's attention.
  • Domain Importance: While the "stalk" domain of MxB is vital for fighting HIV-1, this study found it is largely irrelevant for fighting HCV. Instead, the N-terminal 83 amino acids and the GTPase domain do the heavy lifting.

Key Results

  • Binding Affinity Drop: The presence of MxB causes a 28% decrease in the binding affinity between CypA and NS5A (from -61.57 to -44.14 kcal/mol).
  • Antiviral Loss: Deleting the first 334 residues of MxB completely abolished its ability to inhibit HCV.
  • Structural Stability: MD simulations showed that the predicted ternary complex (CypA–NS5A–MxB) is structurally stable, providing a plausible model for future drug design.

Limitations and Future Work

The authors acknowledge that their structural models, while validated by biochemical assays, are still predictions. Because parts of NS5A and MxB are "intrinsically disordered" (they don't have a fixed shape), they are notoriously difficult to crystallize.

The researchers suggest that future studies using AlphaFold2 or high-resolution Cryo-EM could provide even more precise snapshots of these interactions. This work opens the door to developing "MxB-mimetic" drugs—small molecules that could mimic MxB’s "wedge" effect to treat HCV and other CypA-dependent viruses.

Summary updated

Abstract

The human myxovirus resistance B (MxB) protein is an interferon-induced restriction factor that fights a wide range of viruses. We previously demonstrated that MxB binds to hepatitis C virus (HCV)-encoded non-structural protein 5A (NS5A) and inhibits HCV infection by impairing the formation of cyclophilin A (CypA)-NS5A complex. However, the molecular details about how the presence of MxB diminishes the binding of NS5A to CypA remain uncovered. In this study, through molecular dynamic simulations and biochemical assays, we characterized that MxB binds to NS5A domain I through its N-terminal and GTPase domains. Specifically, amino acids (aa.) 189-191 and aa. 330-334 within MxB, together with NS5A residues aa. 71-73, are crucial for MxB-NS5A interaction. Furthermore, we predicted the CypA:NS5A and CypA:NS5A:MxB complexes and calculated the per-residue energy decomposition for identified key residues of the CypA-NS5A interface. A 28% decrease in CypA-NS5A binding affinity was observed in the presence of MxB, suggesting a weakened CypA-NS5A association upon binding of MxB to NS5A, which may contribute to the MxB-mediated inhibitory effect on the formation of CypA-NS5A complex. This work provides information for the antiviral mechanism of MxB and may facilitate the discovery of new strategies to combat CypA-dependent viruses.
BibTeX
@inproceedings{li2022mxb,
  author = {Quanjie Li and Ni An and Yin Xiao and Ruixin Zhang and Huihan Shao and Dongrong Yi and Shan Cen},
  title = {{MxB Disrupts Hepatitis C Virus NS5A–CypA Complex: Insights From a Combined Theoretical and Experimental Approach}},
  booktitle = {Frontiers in Microbiology},
  year = {2022},
  doi = {10.3389/fmicb.2022.849084},
}
Figure